Idea or Concept – Page 2

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

1 month ago talkbio0Tagged biotech, Blackfoot language, Clinical Trials, Cylembio, Drops - Drug Form, etimupepimut, Hazard Ratio, Io satellite, Keytruda, melanoma, Overall Survival, P-Value, pembrolizumab, Phase 3, Progression-Free Survival, United States Food and Drug Administration

Cylembio; IO Biotech; melanoma; Phase 3; pivotal trial; progression-free survival (PFS); hazard ratio 0.77; p-value 0.056; Keytruda (pembrolizumab); FDA BLA; overall survival (OS) trend; IOB-013/KN-D18; NCT05155254; imsapepimut; etimupepimut; stock drop

AI, Media and the Evolution of Omnichannel in Healthcare Marketing — Ray Rosti on Episode 3 of The Next Marketing with HJ

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Automation, Biomechanical compliance, Communications Media, connected journeys, content intelligence, Doceree, Engaged to be married, Health Care Market, Hereditary Coproporphyria, Klick Media, Measurement, omnichannel, Optimization, personalization, Pharma, Privacy, Region of interest:Presence or Identity:Point in time:*:Nominal

AI in healthcare marketing; omnichannel; first‑party data; content intelligence; media optimization; privacy and compliance; measurement and ROI; pharma marketing; Klick Media; Doceree; HCP engagement; personalization; automation; connected journeys

Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data

1 month ago talkbio0Tagged earnings, Eli, Eli Lilly, Expectations, franchise, Glucagon-Like Peptide 1, Obesity, Oral cavity, orforglipron, Q2 2025, regulatory submission, Weight Loss

Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations

Praxis touts ‘best-in-disease’ epilepsy data, but shares dip

1 month ago talkbio0Tagged anti-seizure medication, Clinical Research, Clinical Trials, Epilepsy, focal onset seizures, Market, Praxis Precision Medicines, Radiant heater, Seizures, vormatrigine

Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market

Trump Administration Unveils Health Data Sharing Scheme Backed by Apple, Amazon, and Others

1 month ago talkbio0Tagged Administration occupational activities, Amazona, CMS Interoperability Framework, digital health records, Genus Malus, health data, Privacy, tech partnerships, Transplant Registry Unified Management Program

Trump administration; health data sharing; CMS Interoperability Framework; Apple; Amazon; digital health records; patient data; privacy; tech partnerships

Vinay Prasad Departs FDA Amid Conservative Criticism and Sarepta Gene Therapy Controversy

1 month ago talkbio0Tagged CBER, conservative criticism, departure - ActRelationshipType, Drug Approval, gene therapy, Muscular Dystrophy, Duchenne, Prasad, Transplant Registry Unified Management Program, United States Food and Drug Administration, Vinay

Vinay Prasad; FDA; departure; Sarepta Therapeutics; gene therapy; Duchenne muscular dystrophy; conservative criticism; CBER; drug approval controversy; Trump administration

RFK Jr. Reportedly Weighs Preventive Services Panel Revamp, Raising Risks for HIV PrEP Drugmakers

2 months ago talkbio0Tagged Advisory Committees, drugmakers, health disparity, HIV Prevention, Insurance, PREP gene, preventive services panel, public health policy, revamp, RFK Jr., USPSTF

RFK Jr.; preventive services panel; USPSTF; PrEP; HIV prevention; insurance coverage; public health policy; drugmakers; health disparities; revamp; task force

Rethinking Clinical Trial Data in the Era of Decentralization: Key Trends and Challenges (2025)

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Clinical Trials, Data Integration, Data Quality, DCT gene, decentralized, Diversity, Preventive monitoring, regulatory guidance, Remote, risk-based oversight, trials

decentralized clinical trials; DCT; data quality; patient diversity; remote monitoring; AI in trials; data integration; risk-based oversight; clinical trial data; regulatory guidance

Trinity Biotech Repositions for AI-Driven Growth with CGM+ Biosensor Platform

2 months ago talkbio0Tagged AI-powered healthcare, biotech, CGM, chronic disease management, continuous glucose monitor, digital health, multi-sensor, Precision Medicine, Predictive analytics, Trinity (ethnic group), wearable biosensor

Trinity Biotech; CGM+; AI-powered healthcare; digital health; continuous glucose monitor; wearable biosensor; multi-sensor data; predictive analytics; personalized medicine; chronic disease management

How Data Secrecy Is Stalling Progress in Cell and Gene Therapy (2025)

2 months ago talkbio0Tagged Cell Therapy, confidentiality, data secrecy, gene therapy, Intellectual Property, regulatory barriers

data secrecy; cell therapy; gene therapy; data sharing; intellectual property; patient privacy; regulatory barriers